HIGH-VOLUME · FEMALE-LED
upadacitinib Side Effects
upadacitinib (also sold as Rinvoq) is HIGH-VOLUME in this FAERS book #99 of 524 by FAERS report count. Signature opener: FEMALE-LED - 71% of sex-coded reports are female (48,021 F / 20,013 M).
Data updated 2026-05-15
- 72,798
- FAERS reports
FAERS voluntary reports, 2016 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
upadacitinib reporting skew - 71% of sex-coded reports are female (48,021 F / 20,013 M). Volume band HIGH-VOLUME #99 of 524 by FAERS report count; caseload CASELOAD.
High-report extract for upadacitinib (Rinvoq): 72,798 FAERS rows (2016-2025). Top named reactions: PAIN, ARTHRALGIA, COVID-19. Outcome stamps DEATH-MARKED · HOSP-MID · FEMALE-LED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2016–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
PAIN leads 4,942 of 72,798 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (71% of sex-coded rows)
Age peak 45-64 (17,577 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 2,641 reports (3.6% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 1,572 |
| PNEUMONIA | 206 |
| COVID-19 | 131 |
| DYSPNOEA | 129 |
| PYREXIA | 115 |
| INFECTION | 114 |
| MALAISE | 113 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 107 |
| RHEUMATOID ARTHRITIS | 106 |
| PAIN | 105 |
| DIARRHOEA | 101 |
| HYPERTENSION | 101 |
| VOMITING | 101 |
| FATIGUE | 100 |
| NASOPHARYNGITIS | 100 |
| CONDITION AGGRAVATED | 98 |
| ABDOMINAL PAIN UPPER | 97 |
| ARTHRALGIA | 97 |
| NAUSEA | 97 |
| DUODENAL ULCER PERFORATION | 96 |
Reactions in Hospitalization Reports
Hospitalization mid-share (17,708, 24.3%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| PNEUMONIA | 1,209 |
| PAIN | 1,201 |
| COVID-19 | 1,089 |
| FALL | 1,025 |
| ARTHRALGIA | 998 |
| PYREXIA | 726 |
| RHEUMATOID ARTHRITIS | 723 |
| URINARY TRACT INFECTION | 690 |
| FATIGUE | 645 |
| DYSPNOEA | 644 |
| DIARRHOEA | 626 |
| VOMITING | 588 |
| PAIN IN EXTREMITY | 585 |
| NAUSEA | 578 |
| MALAISE | 542 |
| SEPSIS | 520 |
| ASTHENIA | 491 |
| BACK PAIN | 478 |
| HOSPITALISATION | 471 |
How to read upadacitinib FAERS figures (CASELOAD · DEATH-MARKED · HOSP-MID)
FAERS holds 72,798 voluntary reports linked to upadacitinib (Rinvoq), 2016-2025. Death is listed on 2,641 (3.6%). Hospitalization appears on 17,708 (24.3%). Top co-reported indication: Rheumatoid Arthritis.
CASELOAD books overweight common drugs and loud reporting cultures; FEMALE-LED is the page opener, not a per-patient risk.
Read with upadacitinib
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 72,729 FAERS cases (Δ 69 lighter vs upadacitinib); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 73,430 FAERS cases (Δ 632 heavier vs upadacitinib); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 72,146 FAERS cases (Δ 652 lighter vs upadacitinib); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 72,117 FAERS cases (Δ 681 lighter vs upadacitinib); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 58.5 pp vs upadacitinib's DEATH-MARKED): CASELOAD · HOSP-MID.
upadacitinib sits in CASELOAD; high report volume tracks exposure and reporting culture more than per-patient risk. Methodology states the de-dup rules.